Press releases
- Neurocrine Biosciences to Participate at Investor Conferences in June
- Neurocrine Biosciences Announces CEO Succession Plan
- Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
- Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules
- Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
- Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
- Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
- Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
More ▼
Key statistics
On Friday, Neurocrine Biosciences Inc (NB3:BER) closed at 125.40, -6.66% below its 52-week high of 134.35, set on Apr 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 125.40 |
---|---|
High | 125.40 |
Low | 125.40 |
Bid | 124.70 |
Offer | 124.95 |
Previous close | 123.20 |
Average volume | 61.00 |
---|---|
Shares outstanding | 100.64m |
Free float | 98.82m |
P/E (TTM) | 37.21 |
Market cap | 13.63bn USD |
EPS (TTM) | 3.64 USD |
Data delayed at least 15 minutes, as of May 31 2024 07:08 BST.
More ▼